share_log

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 Second Quarter Results

Walgreens Boots Alliance | 8-K: Current report

沃尔格林-联合博姿 | 8-K：重大事件
美股sec公告 ·  03/28 07:19
Moomoo AI 已提取核心信息
On March 28, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending February 29, 2024. The company experienced a second-quarter loss per share of $6.85, primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Despite this, adjusted earnings per share (EPS) rose by 3.4% to $1.20, attributed to a lower adjusted effective tax rate and improved U.S. Healthcare profitability. Quarterly sales increased by 6.3% year-over-year to $37.1 billion. WBA narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, citing a challenging U.S. retail environment and other factors, while maintaining its U.S. Healthcare adjusted EBITDA guidance. The company's CEO, Tim Wentworth, expressed optimism about U.S. Healthcare's positive adjusted EBITDA and the company's execution in pharmacy services. WBA also announced a strategic portfolio review over the next three months to drive growth and deliver value.
On March 28, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending February 29, 2024. The company experienced a second-quarter loss per share of $6.85, primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Despite this, adjusted earnings per share (EPS) rose by 3.4% to $1.20, attributed to a lower adjusted effective tax rate and improved U.S. Healthcare profitability. Quarterly sales increased by 6.3% year-over-year to $37.1 billion. WBA narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, citing a challenging U.S. retail environment and other factors, while maintaining its U.S. Healthcare adjusted EBITDA guidance. The company's CEO, Tim Wentworth, expressed optimism about U.S. Healthcare's positive adjusted EBITDA and the company's execution in pharmacy services. WBA also announced a strategic portfolio review over the next three months to drive growth and deliver value.
2024年3月28日，Walgreens Boots Alliance, Inc.（WBA）公布了截至2024年2月29日的财季财务业绩。该公司第二季度每股亏损6.85美元，这主要是由于与VillageMD商誉相关的58亿美元税后非现金减值费用。尽管如此，调整后的每股收益（EPS）增长了3.4％，至1.20美元，这要归因于调整后的有效税率降低和美国医疗保健盈利能力的提高。季度销售额同比增长6.3％，达到371亿美元。WBA以美国零售环境艰难和其他因素为由，将2024财年调整后的每股收益预期缩小至3.20美元至3.35美元，同时维持其经美国医疗保健调整后的息税折旧摊销前利润指引。该公司首席执行官蒂姆·温特沃斯对美国医疗保健调整后的息税折旧摊销前利润和该公司在药房服务方面的执行表示乐观。WBA还宣布了未来三个月的战略投资组合审查，以推动增长并创造价值。
2024年3月28日，Walgreens Boots Alliance, Inc.（WBA）公布了截至2024年2月29日的财季财务业绩。该公司第二季度每股亏损6.85美元，这主要是由于与VillageMD商誉相关的58亿美元税后非现金减值费用。尽管如此，调整后的每股收益（EPS）增长了3.4％，至1.20美元，这要归因于调整后的有效税率降低和美国医疗保健盈利能力的提高。季度销售额同比增长6.3％，达到371亿美元。WBA以美国零售环境艰难和其他因素为由，将2024财年调整后的每股收益预期缩小至3.20美元至3.35美元，同时维持其经美国医疗保健调整后的息税折旧摊销前利润指引。该公司首席执行官蒂姆·温特沃斯对美国医疗保健调整后的息税折旧摊销前利润和该公司在药房服务方面的执行表示乐观。WBA还宣布了未来三个月的战略投资组合审查，以推动增长并创造价值。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息